$IPHAKey Words: Innate Pharma S.A. (NASDAQ: IPHA) shares gained 40.9% to close at $8.10 as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology (ESMO21) Congress 2021. SVB Leerink maintained Innate Pharma with an Outperf